A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 304-307

  Wiersma, Valerie R ^a   He, Yuan ^a   Samplonius, Douwe F ^a   van Ginkel, Robert J ^a   Gerssen, Jurjen ^a   Eggleton, Paul ^b,c   Zhou, Jin ^d   Bremer, Edwin ^a,d   Helfrich, Wijnand ^a,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; CD47; Phagocytosis; Rituximab; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CD47 ANTIGEN; CETUXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL SURFACE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GRANULOCYTE; HUMAN; LETTER; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CD47; PHAGOCYTOSIS; RITUXIMAB; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; PHAGOCYTOSIS; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84891630296     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12617     Document Type: Letter

References (10)

1. Bremer, E., Kuijlen, J., Samplonius, D., Walczak, H., de Leij, L. & Helfrich, W. (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. International Journal of Cancer, 109, 281-290.
2. Bremer, E., de Bruyn, M., Wajant, H. & Helfrich, W. (2009) Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Current Drug Targets, 10, 94-103.
3. Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M., Cha, A.C., Chan, C.K., Tan, B.T., Park, C.Y., Zhao, F., Kohrt, H.E., Malumbres, R., Briones, J., Gascoyne, R.D., Lossos, I.S., Levy, R., Weissman, I.L. & Majeti, R. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 699-713.
4. Chao, M.P., Tang, C., Pachynski, R.K., Chin, R., Majeti, R. & Weissman, I.L. (2011) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood, 118, 4890-4901.
5. Fox, N.L., Humphreys, R., Luster, T.A., Klein, J. & Gallant, G. (2010) Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opinion on Biological Therapy, 10, 1-18.
6. Kikuchi, Y., Uno, S., Yoshimura, Y., Otabe, K., Iida, S., Oheda, M., Fukushima, N. & Tsuchiya, M. (2004) A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells. Biochemical and Biophysical Research Communications, 315, 912-918.
7. Kim, D., Wang, J., Willingham, S.B., Martin, R., Wernig, G. & Weissman, I.L. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia, 26, 2538-2545.
8. Oldenborg, P.A., Gresham, H.D. & Lindberg, F.P. (2001) CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. Journal of Experimental Medicine, 193, 855-862.
9. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., Lovelace, P., Scheeren, F.A., Chao, M.P., Weiskopf, K., Tang, C., Volkmer, A.K., Naik, T.J., Storm, T.A., Mosley, A.R., Edris, B., Schmid, S.M., Sun, C.K., Chua, M.S., Murillo, O., Rajendran, P., Cha, A.C., Chin, R.K., Kim, D., Adorno, M., Raveh, T., Tseng, D., Jaiswal, S., Enger, P.O., Steinberg, G.K., Li, G., So, S.K., Majeti, R., Harsh, G.R., van de Rijn, M., Teng, N.N., Sunwoo, J.B., Alizadeh, A.A., Clarke, M.F. & Weissman, I.L. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 109, 6662-6667.
10. Zhao, X.W., van Beek, E.M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M.A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., Birnbaum, D., van Elsas, A., Kuijpers, T.W., Bertucci, F. & van den Berg, T.K. (2011) CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proceedings of the National Academy of Sciences of the United States of America, 108, 18342-18347.